AIM To test the hypothesis that intravenous liposomal prostaglandin E 1 (Lipo PGE 1) would attenuate reperfusion injury in a rabbit ischemia reperfusion model. METHODS Twenty four open chest rabbits were randomized to receive a 10 minute intravenous infusion of either liposome diluent (placebo), free PGE 1 (2 ?g?kg -1 ), or Lipo PGE 1(2 ?g?kg -1 PGE 1) after 60 minutes of left anterior desending (LAD) ligation just before reperfusion. Carotid arterial pressure and electrocardiogram were monitored and recorded continously throughout the whole experiment. After 2 hours reperfusion, infarct size and region at risk were measured by postmortem dual dyes with triphenyl tetrazolium chloride (TTC) and Evans blue. Myocardial leukocyte infiltration by myeloperoxidase (MPO) assay was performed. RESULTS Infarct size as a ratio of weight of infarcted tissue to weight of region at risk (MI/RISK) was significantly reduced with Lipo PGE 1 32.20%?4.70% compared with PGE 1 42.09%?6.93% or placebo 44.57%?5.46% ( P

OBJECTIVE: To determine the effect of trimetazidine on cardiac function and exercise tolerance in primary hypertension patients with type 2 diabetic. METHODS: In this randomized, double-blind, placebo-controlled prospective study, 60 primary hypertensive patients with diabetic were equally assigned into two groups, patients received trimetazidine (20 mg, 3 times a day) or placebo for 1 year. Echocardiography, cardiopulmonary exercise testing were performed; and the plasma N terminal pro B type natriuretic peptide (NT-ProBNP), hr-CRP, TNF-α, angiotensin Ⅱ and endothelin concentration were determined before and after treatment. RESULTS: In trimetazidine group, the left ventricular mass index, the mitral flow velocity E wave to A wave ratio (E/A), the peak early diastolic velocity (V) to late diastolic velocity (V) ratio (V/V) and the peak systolic velocity (Vs) were significantly improved, the plasma NT-ProBNP level was significantly decreased, and the exercise time, metabolic equivalent, maximal oxygen uptake and anaerobic threshold were significantly increased (all <0.05); plasma concentration of hr-CRP, TNF-α, angiotensin Ⅱ and endothelin were significantly reduced after trimetazidine treatment, compared with baseline (all <0.05) and with placebo (all <0.05). There were no significant differences in any of above parameters after treatment in placebo group (all >0.05). No severe adverse reaction was observed in both groups. CONCLUSIONS For patients with both hypertension and diabetes, trimetazidine can improve cardiac function and increase exercise tolerance.
Diabetes Complications ; complications ; Diabetes Mellitus ; drug therapy ; Double-Blind Method ; Exercise Tolerance ; drug effects ; Heart ; drug effects ; Humans ; Hypertension ; complications ; drug therapy ; Natriuretic Peptide, Brain ; blood ; Prospective Studies ; Treatment Outcome ; Trimetazidine ; pharmacology ; therapeutic use ; Vasodilator Agents ; pharmacology ; therapeutic use